Please assess the completion status of the following clinical trial:

Trial Title: Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histopathologically confirmed Mycosis fungoides or Sézary syndrome (CTCL stage ≥ Ib according to EORTC-ISCL consensus classification) at study entry with progressive, persistant or recurrent disease~* Pretreatment with at least one topical or systemic CTCL therapy or UV therapy, if the prior therapy is not possible anymore or if there is new contraindication or unsatisfactory response~* Karnofsky index ≥70 % (according to Karnofsky DA, Burchenal JH. (1949). The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press. Page 196)~* Life expectancy \> 3 months~* Age ≥ 18 years~* Adequate organ function:~* differential blood count: hemoglobin ≥ 10 g/dl without transfusions, leukocyte count \> 3000/µl, lymphocyte count \> 700/µl~* liver enzymes ≤ 2 x upper limit of normal (ULN)~* serum creatinine ≤ 1.5 mg/dl or calculate creatinine clearance ≥ 50 ml/min,~* Negative Pregnancy test from blood, agreement for efficient contraception in male and female patients unless infertility is documented (DMF is not approved during pregnancy)~* Ability to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study~* written informed consent must be given according to ICH/GCP, and national/local regulations, before patient registration and prior to any study specific procedures.~Exclusion criteria:~* Another active malignant disease with the following exceptions:~* Basal or squamous cell carcinoma of the skin~* In situ carcinoma of the cervix or the skin~* Topical chemotherapy, superficial radiotherapy, photopheresis or systemic CTCL treatment within 28 days before study therapy initiation~* Severe systemic disease or infection at study therapy initiation~* Prior treatment with DMF or simultaneous topical DMF treatment~* Contraindications for treatment with DMF (known hypersensibility to the drug, severe gastrointestinal disease (like ulcerations), Alcohol abuse, other obligately liver- or nephrotoxic medication, known clinically apparent renal or hepatic insufficiency)~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Participation in other clinical studies within 14 days before study therapy initiation~* Pregnant or lactating patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete